S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Monte Rosa Therapeutics Stock Price, News & Analysis (NASDAQ:GLUE)

$4.33
+0.66 (+17.98%)
(As of 12/8/2023 ET)
Compare
Today's Range
$3.53
$4.42
50-Day Range
$2.50
$5.07
52-Week Range
$2.44
$9.65
Volume
568,057 shs
Average Volume
196,913 shs
Market Capitalization
$216.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33

Monte Rosa Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
207.9% Upside
$13.33 Price Target
Short Interest
Bearish
9.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Monte Rosa Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.56) to ($2.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

653rd out of 954 stocks

Biological Products, Except Diagnostic Industry

85th out of 128 stocks


GLUE stock logo

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

GLUE Stock Price History

GLUE Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Monte Rosa Therapeutics: Q3 Earnings Insights
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
GLUE - Monte Rosa Therapeutics, Inc.
See More Headlines
Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLUE
Fax
N/A
Employees
133
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.33
High Stock Price Target
$18.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+231.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-108,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.61 per share

Miscellaneous

Free Float
47,427,000
Market Cap
$201.33 million
Optionable
Not Optionable
Beta
0.98
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Markus Warmuth M.D. (Age 52)
    President, CEO & Director
    Comp: $901.35k
  • Dr. Owen B. Wallace Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $630.68k
  • Dr. Filip Janku M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $658.66k
  • Ms. Jennifer Champoux
    Chief People & Operations Officer
  • Dr. Sharon Townson Ph.D. (Age 48)
    Chief Technology Officer
  • Mr. Philip Nickson J.D. (Age 44)
    Ph.D., General Counsel
  • Dr. John C. Castle Ph.D. (Age 52)
    Chief Data Scientist
  • Dr. Jullian G. Jones J.D. (Age 47)
    M.B.A., Ph.D., Chief Business Officer
  • Mr. Magnus Walter DPHIL
    Senior Vice President of Chemical Sciences & Process Development
  • Mr. Edmund Dunn (Age 57)
    Vice President & Corporate Controller














GLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Monte Rosa Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GLUE shares.
View GLUE analyst ratings
or view top-rated stocks.

What is Monte Rosa Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 12-month price objectives for Monte Rosa Therapeutics' stock. Their GLUE share price targets range from $11.00 to $18.00. On average, they anticipate the company's stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 207.9% from the stock's current price.
View analysts price targets for GLUE
or view top-rated stocks among Wall Street analysts.

How have GLUE shares performed in 2023?

Monte Rosa Therapeutics' stock was trading at $7.61 at the beginning of 2023. Since then, GLUE stock has decreased by 43.1% and is now trading at $4.33.
View the best growth stocks for 2023 here
.

When is Monte Rosa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our GLUE earnings forecast
.

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its earnings results on Thursday, November, 9th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.05.

What ETF holds Monte Rosa Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 18,664 shares of GLUE stock, representing 1.26% of its portfolio.

When did Monte Rosa Therapeutics IPO?

(GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

Who are Monte Rosa Therapeutics' major shareholders?

Monte Rosa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (11.99%), Northern Trust Corp (0.89%), Charles Schwab Investment Management Inc. (0.49%), TD Asset Management Inc (0.39%), California State Teachers Retirement System (0.09%) and Legal & General Group Plc (0.07%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GLUE) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -